BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,070 filers reported holding BAXTER INTL INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 312,400 | $25,126,000 | 9.98% |
| GENERATION INVESTMENT MANAGEMENT LLP | 20,737,864 | $1,667,946,000 | 6.93% |
| NUANCE INVESTMENTS, LLC | 4,413,191 | $354,953,000 | 6.50% |
| Soditic Asset Management LLP | 147,620 | $11,873,000 | 5.62% |
| PRAGMA GESTAO DE PATRIMONIO LTD | 145,000 | $11,662 | 5.32% |
| Veritas Asset Management LLP | 11,124,677 | $894,758,000 | 5.14% |
| Dash Acquisitions Inc. | 97,091 | $7,809,000 | 4.07% |
| SECTOR GAMMA AS | 237,429 | $19,096,000 | 3.81% |
| Glenview Capital Management | 2,167,722 | $174,350,000 | 3.16% |
| Cincinnati Specialty Underwriters Insurance CO | 96,500 | $7,761,000 | 3.12% |
| Haverford Financial Services, Inc. | 158,462 | $12,745,000 | 3.10% |
| TSFG, LLC | 98,301 | $7,906,000 | 3.09% |
| Asymmetry Capital Management, L.P. | 61,570 | $4,952,000 | 2.98% |
| Dundas Partners LLP | 259,020 | $20,833,000 | 2.94% |
| CINCINNATI FINANCIAL CORP | 1,370,648 | $110,241,000 | 2.71% |
| PENSIOENFONDS RAIL & OV | 1,235,082 | $99,683,000 | 2.52% |
| Foyston, Gordon, & Payne Inc | 121,808 | $9,797,000 | 2.45% |
| Sivik Global Healthcare LLC | 115,000 | $9,249,000 | 2.21% |
| Canal Insurance CO | 70,000 | $5,630,000 | 1.91% |
| Haverford Trust Co | 1,789,148 | $143,901,000 | 1.72% |
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BAXTER INTL INC's shareholders in Q3 2021. To view BAXTER INTL INC's shareholder history, click here.